NCT03296553View on ClinicalTrials.gov

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

August 26, 2019

Study Completion Date

August 26, 2019

Conditions
Kaposi SarcomaHuman Immunodeficiency VirusImmune Reconstitution Syndrome
Interventions
DRUG

Valganciclovir

The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.

DRUG

Antiretroviral Combinations

Patients will receive standard antiretroviral treatment as recommended

Trial Locations (1)

14080

Instituto Nacional de Cancerologia, Mexico City

All Listed Sponsors
collaborator

Instituto Nacional de Enfermedades Respiratorias

OTHER_GOV

lead

National Institute of Cancerología

OTHER_GOV

NCT03296553 - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. | Biotech Hunter | Biotech Hunter